Date | Time | Source | Headline | Symbol | Company |
11/16/2009 | 7:18PM | Dow Jones News | Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30 | NYSE:FRX | Forest Road Acquisition Corp |
11/12/2009 | 7:02AM | Marketwired | CL, EJ, GME, HSY, CNW and FRX Free Research report on BenchmarkJournal.com | NYSE:FRX | Forest Road Acquisition Corp |
11/09/2009 | 12:14PM | Dow Jones News | Forest Labs In Tentative Pact To Settle US Civil Probe | NYSE:FRX | Forest Road Acquisition Corp |
11/09/2009 | 9:05AM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NYSE:FRX | Forest Road Acquisition Corp |
11/03/2009 | 6:02AM | Marketwired | AnalystChoice.com Provides Analytical Coverage on XOM, SCG, FRX, WL, AVB and HXL | NYSE:FRX | Forest Road Acquisition Corp |
11/02/2009 | 9:52PM | Business Wire | Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation | NYSE:FRX | Forest Road Acquisition Corp |
10/29/2009 | 5:54AM | Dow Jones News | Richter To Start Late Stage Tests On Key Schizophrenia Drug | NYSE:FRX | Forest Laboratories Inc. |
10/29/2009 | 4:47AM | Dow Jones News | Hungary Richter, US Forest Announce Positive Drug Tests | NYSE:FRX | Forest Laboratories Inc. |
10/28/2009 | 2:05PM | Business Wire | Forest Laboratories, Inc. & Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment ... | NYSE:FRX | Forest Road Acquisition Corp |
10/23/2009 | 7:12AM | Marketwired | WFC, AAP, EJ, CBE, FRX and DFS Receiving Professional Financial Coverage from RothmanResearch.com | NYSE:FRX | Forest Road Acquisition Corp |
10/21/2009 | 12:31PM | Edgar (US Regulatory) | Current report filing (8-K) | NYSE:FRX | Forest Road Acquisition Corp |
10/20/2009 | 10:19AM | Dow Jones News | CORRECT: Forest Labs 2Q Net Drops 23% On Charges | NYSE:FRX | Forest Road Acquisition Corp |
10/20/2009 | 9:06AM | Dow Jones News | Forest Labs 2Q Net Drops 23% On Charges; Results Beats Views | NYSE:FRX | Forest Road Acquisition Corp |
10/20/2009 | 8:00AM | Business Wire | Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Cha... | NYSE:FRX | Forest Road Acquisition Corp |
10/17/2009 | 5:00PM | Business Wire | Forest Laboratories & Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain &... | NYSE:FRX | Forest Road Acquisition Corp |
10/14/2009 | 5:44AM | Marketwired | TheFortuneFinacial.com Progressive Review on BDN, EXH, GME, CL, FRX and LMT | NYSE:FRX | Forest Road Acquisition Corp |
10/05/2009 | 8:00AM | Business Wire | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 Second Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
10/05/2009 | 6:16AM | Marketwired | WallStSense.com Fundamental & Technical Coverage of FRX, AVT, LUK, MWV, DPS and PL | NYSE:FRX | Forest Road Acquisition Corp |
09/22/2009 | 6:24AM | Marketwired | BenchmarkJournal.com Free Analyst Review for ARE, CL, EJ, FRX, AVB and COT | NYSE:FRX | Forest Road Acquisition Corp |
09/17/2009 | 4:57PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:FRX | Forest Road Acquisition Corp |
09/12/2009 | 2:35PM | Business Wire | Forest Laboratories Presents Analysis of Two Positive Pivotal Phase III Studies of Ceftaroline for the Treatment of Community... | NYSE:FRX | Forest Road Acquisition Corp |
09/09/2009 | 7:17AM | Marketwired | AnalystChoice.com Brings You the Best Complimentary Research Report on MWV, DFS, WDR, DHR, FRX and WTSLA | NYSE:FRX | Forest Road Acquisition Corp |
08/27/2009 | 6:45PM | Business Wire | Forest Laboratories, Inc. & Nycomed Announce a Conference Call to Review Publication of Daxas® Phase III Clinical Trial Results | NYSE:FRX | Forest Road Acquisition Corp |
08/27/2009 | 6:35PM | Business Wire | Four Studies Published in The Lancet Show Roflumilast (Daxas®), a New Oral Approach to COPD, Improves Lung Function & Reduce... | NYSE:FRX | Forest Road Acquisition Corp |
08/27/2009 | 6:31PM | PR Newswire (US) | Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce | NYSE:FRX | |
08/26/2009 | 6:22AM | Marketwired | RothmanResearch.com Stock Review for UIS, BEN, AVT, FRX, BKD and LIZ | NYSE:FRX | Forest Road Acquisition Corp |
08/19/2009 | 9:50AM | Dow Jones News | 2nd UPDATE: Glenmark, Forest Say Their Drug Failed In Trials | NYSE:FRX | Forest Laboratories Inc. |
08/19/2009 | 3:53AM | Dow Jones News | UPDATE: Glenmark, Forest Say Oglemilast Failed In Key Study | NYSE:FRX | Forest Laboratories Inc. |
08/18/2009 | 11:00PM | Business Wire | Forest Announces Phase IIb Study Results For Oglemilast in Chronic Obstructive Pulmonary Disease | NYSE:FRX | Forest Road Acquisition Corp |
08/12/2009 | 6:42AM | Marketwired | TheFortuneFinancial.com Free Market Research on APH, HOG, FRX, DOX, LIZ and ITT | NYSE:FRX | Forest Road Acquisition Corp |